Arqule : Nanotech zum Schnäppchenpreis ! - 500 Beiträge pro Seite
eröffnet am 19.06.03 20:00:37 von
neuester Beitrag 09.09.03 18:40:36 von
neuester Beitrag 09.09.03 18:40:36 von
Beiträge: 24
ID: 744.982
ID: 744.982
Aufrufe heute: 0
Gesamt: 1.696
Gesamt: 1.696
Aktive User: 0
ISIN: US04269E1073 · WKN: 903396
17,930
EUR
-0,11 %
-0,020 EUR
Letzter Kurs 15.01.20 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0000 | +67,36 | |
| 2,7500 | +38,19 | |
| 1,4800 | +33,82 | |
| 0,7900 | +27,42 | |
| 7,6500 | +20,09 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -15,56 | |
| 1,0480 | -16,56 | |
| 6,5500 | -18,13 | |
| 0,6021 | -35,26 | |
| 3,6800 | -47,05 |
Feedback
THURSDAY, JUNE 19, 2003 7:00 AM
- PR Newswire
WOBURN, Mass., Jun 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- ArQule, Inc. (ARQL) , a drug discovery and development company, today announced that a lead compound from its p38 MAP Kinase program has demonstrated functional oral activity in a rat model of rheumatoid arthritis. In this established model, the data show that ArQule`s compound reduced joint swelling in a dose-dependent manner and was well tolerated at all doses studied. The study details will be featured as part of ArQule`s corporate presentation at the BIO 2003 investor forum and will be webcast live on Wednesday, June 25 at 2:00 P.M. ET on ArQule`s website, www.ArQule.com.
Dr. Stephen A. Hill, ArQule`s President and CEO, said, "I am very encouraged by this positive preclinical data, which complements a balance of potency, selectivity, and absorption, and in vivo pharmacokinetic data. I believe the speed at which we have reached this point validates our multi- dimensional approach to lead generation and lead optimization. We remain on track to identify a GLP-tox candidate before the end of the year."
The p38 MAP Kinase compound studied represents the first in a series of ArQule-designed, wholly owned compounds to progress into lead optimization, having achieved target criteria for potency, selectivity and absorption, in vivo pharmacokinetics and functional activity. The goal of lead optimization is to identify one or more Optimal Chemical Entities(TM) (OCEs(TM)) for advancement into toxicology testing, the final stage in preparation for an Investigational New Drug (IND) filing with the FDA.
"The results of our rheumatoid arthritis animal study mark a significant achievement in the p38 MAP Kinase program," said Dr. Andrew C.G. Uprichard, ArQule`s Vice President and Chief Operating Officer. "These in vivo data confirm our earlier findings that our lead series appears to contain compounds that can be administered orally and may be useful in treating the target indication."
The seven-day, collagen-induced arthritis study compared ArQule`s lead compound at three different doses with normal controls, arthritis controls and arthritis-induced animals treated with the steroid dexamethasone. All animals were dosed orally twice a day and daily measurements of ankle diameter and body weight were taken. Additional assessments, including histopathology of the joints, are ongoing. Significant differences from vehicle-treated arthritis controls were seen at all doses studied, with reduction of joint size to normal levels in the middle and high dose groups.
As a next step for this series, ArQule will select at least two compounds for pilot toxicology studies. In addition to this initial lead compound, ArQule has identified several other compounds from this lead series with similar potency, selectivity, absorption and in vivo oral activity.
ArQule, Inc., a recognized leader in small-molecule chemistry, is pursuing a strategy to become an efficient drug discovery and development company. ArQule provides high quality library design and compound production to pharmaceutical collaborators. The Company also is building a discovery portfolio of small-molecule compounds, or OCEs(TM), that possess the best balance of drug-like properties. In addition, ArQule is focused on acquiring or in-licensing clinical candidates to build a clinical portfolio in a defined therapeutic area.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: that positive early stage preclinical results may not be repeated in later studies or in humans; as a result of unforeseen delays ArQule may not be able to identify a candidate for GLP toxicity testing by the end of 2003; other compounds in the series may not demonstrate favorable characteristics; the ability to design OCEs(TM); the ability to successfully generate compounds using computational compound design technology and predictive models; the progress of product research and development activities in our present portfolio and projected expenditures; the ability to enter into future collaborations with pharmaceutical and biotechnology companies; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this release. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
SOURCE ArQule, Inc.
- PR Newswire
WOBURN, Mass., Jun 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- ArQule, Inc. (ARQL) , a drug discovery and development company, today announced that a lead compound from its p38 MAP Kinase program has demonstrated functional oral activity in a rat model of rheumatoid arthritis. In this established model, the data show that ArQule`s compound reduced joint swelling in a dose-dependent manner and was well tolerated at all doses studied. The study details will be featured as part of ArQule`s corporate presentation at the BIO 2003 investor forum and will be webcast live on Wednesday, June 25 at 2:00 P.M. ET on ArQule`s website, www.ArQule.com.
Dr. Stephen A. Hill, ArQule`s President and CEO, said, "I am very encouraged by this positive preclinical data, which complements a balance of potency, selectivity, and absorption, and in vivo pharmacokinetic data. I believe the speed at which we have reached this point validates our multi- dimensional approach to lead generation and lead optimization. We remain on track to identify a GLP-tox candidate before the end of the year."
The p38 MAP Kinase compound studied represents the first in a series of ArQule-designed, wholly owned compounds to progress into lead optimization, having achieved target criteria for potency, selectivity and absorption, in vivo pharmacokinetics and functional activity. The goal of lead optimization is to identify one or more Optimal Chemical Entities(TM) (OCEs(TM)) for advancement into toxicology testing, the final stage in preparation for an Investigational New Drug (IND) filing with the FDA.
"The results of our rheumatoid arthritis animal study mark a significant achievement in the p38 MAP Kinase program," said Dr. Andrew C.G. Uprichard, ArQule`s Vice President and Chief Operating Officer. "These in vivo data confirm our earlier findings that our lead series appears to contain compounds that can be administered orally and may be useful in treating the target indication."
The seven-day, collagen-induced arthritis study compared ArQule`s lead compound at three different doses with normal controls, arthritis controls and arthritis-induced animals treated with the steroid dexamethasone. All animals were dosed orally twice a day and daily measurements of ankle diameter and body weight were taken. Additional assessments, including histopathology of the joints, are ongoing. Significant differences from vehicle-treated arthritis controls were seen at all doses studied, with reduction of joint size to normal levels in the middle and high dose groups.
As a next step for this series, ArQule will select at least two compounds for pilot toxicology studies. In addition to this initial lead compound, ArQule has identified several other compounds from this lead series with similar potency, selectivity, absorption and in vivo oral activity.
ArQule, Inc., a recognized leader in small-molecule chemistry, is pursuing a strategy to become an efficient drug discovery and development company. ArQule provides high quality library design and compound production to pharmaceutical collaborators. The Company also is building a discovery portfolio of small-molecule compounds, or OCEs(TM), that possess the best balance of drug-like properties. In addition, ArQule is focused on acquiring or in-licensing clinical candidates to build a clinical portfolio in a defined therapeutic area.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: that positive early stage preclinical results may not be repeated in later studies or in humans; as a result of unforeseen delays ArQule may not be able to identify a candidate for GLP toxicity testing by the end of 2003; other compounds in the series may not demonstrate favorable characteristics; the ability to design OCEs(TM); the ability to successfully generate compounds using computational compound design technology and predictive models; the progress of product research and development activities in our present portfolio and projected expenditures; the ability to enter into future collaborations with pharmaceutical and biotechnology companies; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this release. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
SOURCE ArQule, Inc.
Mit über 80 Millionen Cash kann man bei ARQL kaum was falsch machen, zumal am Mittwoch,25.Juni die Details ihrer
Studie in Washington D.C. beim BIO Investor Forum bekanntgegeben werden. Ich denke, daß wir sehr zügig wieder bei 5 USD sind .Bin auf jedenfall positiv gestimmt.
Gruss
Studie in Washington D.C. beim BIO Investor Forum bekanntgegeben werden. Ich denke, daß wir sehr zügig wieder bei 5 USD sind .Bin auf jedenfall positiv gestimmt.
Gruss
... bei aller "Begeisterung" würde ich nun doch mal die Kirche im Dorf lassen. Der Chartverlauf spiegelt eher eine erforderliche deutliche Korrektur einer Blase bei einem marktengen Wert wieder. Da scheint irgendein amerikanischer Börsenbrief kürzlich Kaufempfehlungen ausgesprochen zu haben, alle sind aufgesprungen und jetzt merken die Leute nach und nach, dass die Bäume nicht in den Himmel wachsen. Ich rechne nach den Indikatoren und dem Chartverlauf noch mit deutlichen Korrekturen.
Als völlig absurd empfinde ich, dass am Freitag in Frankfurt knapp 11.800 Stück dieser Aktie gehandelt worden sind, obwohl die Firma einen Börsenwert von gerade mal 100 Mio. US$ hat. Gibt es hier also einen Großinvestor ... oder wahrscheinlich eher viele Kleinanleger, die durch eine (mal wieder) falsche Euphorie in einen völlig überhitzten Wert eingestiegen sind?!
merlone
@ merlone
Schon möglich daß du recht hast, aber ein Unternehmen das im Biotechsektor innerhalb eines Jahres den Verlust derart senken kann und zudem ordentlich Cash besitzt, kann so schlecht nicht sein. Abwarten was sie am Mittwoch zu sagen haben. Wenn die Daten wirklich so positiv sind, ist die Aktie schnell wieder bei 5USD. Dann ist es mir egal wie der Chart aussieht. Ausserdem ist die Aktie vor Freitag 6 Tage nur gefallen. Warten wir es einfach mal ab.
Gruss
Schon möglich daß du recht hast, aber ein Unternehmen das im Biotechsektor innerhalb eines Jahres den Verlust derart senken kann und zudem ordentlich Cash besitzt, kann so schlecht nicht sein. Abwarten was sie am Mittwoch zu sagen haben. Wenn die Daten wirklich so positiv sind, ist die Aktie schnell wieder bei 5USD. Dann ist es mir egal wie der Chart aussieht. Ausserdem ist die Aktie vor Freitag 6 Tage nur gefallen. Warten wir es einfach mal ab.
Gruss
@lucakevin
Hallo lucakevin!
Verrate bitte mal, woher Du das mit den 80 Millionen Kassenbestand hast, über Die Du jetzt schon zweimal gepostest hast
.
Nach den ungeschönten Zahlen sind aber selbst 80 Millionen von ArQule innerhalb eines Jahres verbrannt, wie die Verluste der Vergangenheit zeigen:
Gewinn 1999: -17,4 Mio $
Gewinn 2000: + 3,9 Mio $
Gewinn 2001: -41,0 Mio $
Gewinn 2002: -77,9 Mio $
(Quelle: http://cbs.marketwatch.com/tools/quotes/financials.asp?symb=…)
77,9 Mio Dollar Verlust, das bedeutet, dass ArQule, wenn Du beispielsweise 700,00 € investierst, diese innerhalb von nur vier Minuten verbrannt hat.
Wenn ich langfristig investiere, sollte es schon eine Firma sein, die mein Geld vermehrt.
@merlone
Hallo merlone!
Charttechnisch werde ich Dir recht geben, dass die Notierung tief fällt, wenn der Kurs wieder unter 3,70 $ rutschen sollte. Bis dahin sollte man als Investierter mit Bangen abwarten, aber dann vor dem Sturz zurück in den Abwärtskanal auch wirklich die Reißleine ziehen. Ich habe dazu einen Chart gefunden, der dies verdeutlicht:
Die Marktkapitalisierung beträgt tatsächlich nur 97,60 Mio $. Ein Wunder, dass ArQule in Deutschland fast so rege gehandelt wird, wie an der Nasdaq. Die Marktkapitalisierung liegt in einer Liga mit in Deutschland so bekannten Firmen, wie H&R Wasag (WKN 775700), Simona (WKN 723940), Maxdata (WKN 658130) und Microlog (WKN 549431), wobei alle genannten sogar noch etwas größer sind. Sollte etwa ein deutscher Börsenbrief eine Kaufempfehlung ausgesprochen haben, fühle ich mich etwas an Egbert Prior erinnert
.
Tschüss, klepper63
Hallo lucakevin!
Verrate bitte mal, woher Du das mit den 80 Millionen Kassenbestand hast, über Die Du jetzt schon zweimal gepostest hast
.Nach den ungeschönten Zahlen sind aber selbst 80 Millionen von ArQule innerhalb eines Jahres verbrannt, wie die Verluste der Vergangenheit zeigen:
Gewinn 1999: -17,4 Mio $
Gewinn 2000: + 3,9 Mio $
Gewinn 2001: -41,0 Mio $
Gewinn 2002: -77,9 Mio $
(Quelle: http://cbs.marketwatch.com/tools/quotes/financials.asp?symb=…)
77,9 Mio Dollar Verlust, das bedeutet, dass ArQule, wenn Du beispielsweise 700,00 € investierst, diese innerhalb von nur vier Minuten verbrannt hat.
Wenn ich langfristig investiere, sollte es schon eine Firma sein, die mein Geld vermehrt.
@merlone
Hallo merlone!
Charttechnisch werde ich Dir recht geben, dass die Notierung tief fällt, wenn der Kurs wieder unter 3,70 $ rutschen sollte. Bis dahin sollte man als Investierter mit Bangen abwarten, aber dann vor dem Sturz zurück in den Abwärtskanal auch wirklich die Reißleine ziehen. Ich habe dazu einen Chart gefunden, der dies verdeutlicht:
Die Marktkapitalisierung beträgt tatsächlich nur 97,60 Mio $. Ein Wunder, dass ArQule in Deutschland fast so rege gehandelt wird, wie an der Nasdaq. Die Marktkapitalisierung liegt in einer Liga mit in Deutschland so bekannten Firmen, wie H&R Wasag (WKN 775700), Simona (WKN 723940), Maxdata (WKN 658130) und Microlog (WKN 549431), wobei alle genannten sogar noch etwas größer sind. Sollte etwa ein deutscher Börsenbrief eine Kaufempfehlung ausgesprochen haben, fühle ich mich etwas an Egbert Prior erinnert
.Tschüss, klepper63
Trading Spotlight
WOBURN, Mass., April 16 /PRNewswire-FirstCall/ -- ArQule, Inc. today announced results for its first quarter ended March 31, 2003.
For the quarter, ArQule``s revenues were $15,653,000, compared with $13,968,000, for the same period of 2002. The Company reported a net loss of $750,000, or $0.03 per share, for the first quarter of 2003, compared with a net loss of $8,375,000, or $0.40 per share, for the first quarter of 2002. Net loss for the first quarter of 2002 included stock-based compensation and amortization of purchased intangibles of $1,767,000 and $844,000, respectively.
ArQule ended the first quarter of 2003 with approximately $83 million in cash and marketable securities.
"ArQule delivered a remarkable performance this quarter," said Dr. Stephen A. Hill, ArQule``s President and CEO. "This is a tribute to our employees who, despite the turmoil of the current economic, social and biotechnology investment climate, remained focused on achieving business and science expectations in our core chemistry services business and our internal drug discovery programs."
Dr. Hill continued, "We met all expectations of our pharmaceutical collaborators, which underscores our belief in the value of our core chemistry technology and its potential for further revenue generation. Other highlights of the quarter include ArQule``s success in initiating lead optimization with one chemical series in our internal p38 Map kinase program. Our next milestone in this program will be to select an Optimal Chemical Entity(TM) to advance to a pilot toxicity study before beginning a GLP-toxicity study. Meanwhile, our partnered programs with Wyeth and Solvay continue to progress according to those companies`` internal schedules.
"In addition, during the first quarter, we continued to assess a number of clinical candidates. We are evaluating and prioritizing in-licensing and acquisition opportunities based on scientific, development and financial criteria," concluded Hill.
David C. Hastings, Vice President and CFO, commented, "Our financial results this quarter demonstrate our ability to meet our revenue goals and to progress our internal drug discovery programs while tightly managing our costs. In addition, we announced in March that Pfizer made a $5 million equity investment in ArQule based upon the successful achievement of all production goals for 2002. We are delighted by the outcome of the first year of this seven-year collaboration."
ArQule will hold a conference call at 9:00 a.m. Eastern Time. Dr. Stephen A. Hill, President and CEO, David C. Hastings, Vice President and CFO, and Dr. Andrew C.G. Uprichard, Vice President and COO, will participate in the call.
Date: Wednesday, April 16, 2002 Time: 9:00 a.m. Eastern Time Conference Call Numbers: Toll Free: (800) 289-0493 Toll: (913) 981-5510 Access code: 724118 Webcast: www.ArQule.com
A replay of the conference call will be available for five days and can be accessed by dialing toll-free (888) 203-1112, and outside the U.S. (719) 457- 0820. The access code is 724118.
ArQule, Inc., a recognized leader in small-molecule chemistry, is pursuing a strategy to become an efficient drug discovery and development company. ArQule provides high quality library design and compound production to pharmaceutical collaborators. The Company also is building a discovery portfolio of small-molecule compounds, or Optimal Chemical Entities(TM) (OCEs(TM)), that possess the best balance of drug-like properties. In addition, ArQule is focused on acquiring or in-licensing clinical candidates to build a clinical portfolio in a defined therapeutic area.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule``s operations, development efforts and the business environment, including without limitation: the ability to successfully integrate acquired technologies and assets; the ability to successfully satisfy milestones and deliver compounds to corporate collaborators; the ability to design OCEs(TM); the ability to successfully generate compounds using computational compound design technology and predictive models; the progress of product research and development activities in our present portfolio and projected expenditures; the ability to enter into future collaborations with pharmaceutical and biotechnology companies; the ability to raise additional funds in uncertain equity markets; and, the risks and uncertainties described in ArQule``s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
-- financial tables follow -- ArQule, Inc. Condensed Statement of Operations (In Thousands, Except Per Share Amounts) Three Months Ended March 31 (Unaudited) 2003 2002 Revenue: Compound development revenue $15,653 $13,252 Compound development revenue -- related parties - 716 Total revenue 15,653 13,968 Costs and expenses: Cost of revenue 9,333 8,274 Research and development 4,567 8,150 Marketing, general and administrative 2,647 3,664 Stock-based compensation - 1,767 Amortization of intangibles - 844 Total costs and expenses 16,547 22,699 Loss from operations (894) (8,731) Net investment income 144 356 Net loss $(750) $(8,375) Net loss, excluding acquisition related charges (B) $(750) $(5,764) Diluted net loss per share (A) $(0.03) $(0.40) Diluted net loss per share, excluding acquisition related charges (B) $(0.03) $(0.27) Weighted average common shares outstanding -- Diluted 21,691 21,082 (A) Basic and diluted net loss per share amounts were equal in both periods presented. (B) In 2002, acquisition related charges include amortization of intangible assets and stock-based compensation. March 31, December 31, Balance sheet data (In thousands): 2003 2002 Cash, cash equivalents and marketable securities $82,866 $85,626 Working capital 61,203 54,176 Total assets 142,534 145,079 Stockholders`` equity 97,919 93,715
ArQule, Inc.
© PR Newswire
Quelle:www.finanznachrichten.de
For the quarter, ArQule``s revenues were $15,653,000, compared with $13,968,000, for the same period of 2002. The Company reported a net loss of $750,000, or $0.03 per share, for the first quarter of 2003, compared with a net loss of $8,375,000, or $0.40 per share, for the first quarter of 2002. Net loss for the first quarter of 2002 included stock-based compensation and amortization of purchased intangibles of $1,767,000 and $844,000, respectively.
ArQule ended the first quarter of 2003 with approximately $83 million in cash and marketable securities.
"ArQule delivered a remarkable performance this quarter," said Dr. Stephen A. Hill, ArQule``s President and CEO. "This is a tribute to our employees who, despite the turmoil of the current economic, social and biotechnology investment climate, remained focused on achieving business and science expectations in our core chemistry services business and our internal drug discovery programs."
Dr. Hill continued, "We met all expectations of our pharmaceutical collaborators, which underscores our belief in the value of our core chemistry technology and its potential for further revenue generation. Other highlights of the quarter include ArQule``s success in initiating lead optimization with one chemical series in our internal p38 Map kinase program. Our next milestone in this program will be to select an Optimal Chemical Entity(TM) to advance to a pilot toxicity study before beginning a GLP-toxicity study. Meanwhile, our partnered programs with Wyeth and Solvay continue to progress according to those companies`` internal schedules.
"In addition, during the first quarter, we continued to assess a number of clinical candidates. We are evaluating and prioritizing in-licensing and acquisition opportunities based on scientific, development and financial criteria," concluded Hill.
David C. Hastings, Vice President and CFO, commented, "Our financial results this quarter demonstrate our ability to meet our revenue goals and to progress our internal drug discovery programs while tightly managing our costs. In addition, we announced in March that Pfizer made a $5 million equity investment in ArQule based upon the successful achievement of all production goals for 2002. We are delighted by the outcome of the first year of this seven-year collaboration."
ArQule will hold a conference call at 9:00 a.m. Eastern Time. Dr. Stephen A. Hill, President and CEO, David C. Hastings, Vice President and CFO, and Dr. Andrew C.G. Uprichard, Vice President and COO, will participate in the call.
Date: Wednesday, April 16, 2002 Time: 9:00 a.m. Eastern Time Conference Call Numbers: Toll Free: (800) 289-0493 Toll: (913) 981-5510 Access code: 724118 Webcast: www.ArQule.com
A replay of the conference call will be available for five days and can be accessed by dialing toll-free (888) 203-1112, and outside the U.S. (719) 457- 0820. The access code is 724118.
ArQule, Inc., a recognized leader in small-molecule chemistry, is pursuing a strategy to become an efficient drug discovery and development company. ArQule provides high quality library design and compound production to pharmaceutical collaborators. The Company also is building a discovery portfolio of small-molecule compounds, or Optimal Chemical Entities(TM) (OCEs(TM)), that possess the best balance of drug-like properties. In addition, ArQule is focused on acquiring or in-licensing clinical candidates to build a clinical portfolio in a defined therapeutic area.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule``s operations, development efforts and the business environment, including without limitation: the ability to successfully integrate acquired technologies and assets; the ability to successfully satisfy milestones and deliver compounds to corporate collaborators; the ability to design OCEs(TM); the ability to successfully generate compounds using computational compound design technology and predictive models; the progress of product research and development activities in our present portfolio and projected expenditures; the ability to enter into future collaborations with pharmaceutical and biotechnology companies; the ability to raise additional funds in uncertain equity markets; and, the risks and uncertainties described in ArQule``s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
-- financial tables follow -- ArQule, Inc. Condensed Statement of Operations (In Thousands, Except Per Share Amounts) Three Months Ended March 31 (Unaudited) 2003 2002 Revenue: Compound development revenue $15,653 $13,252 Compound development revenue -- related parties - 716 Total revenue 15,653 13,968 Costs and expenses: Cost of revenue 9,333 8,274 Research and development 4,567 8,150 Marketing, general and administrative 2,647 3,664 Stock-based compensation - 1,767 Amortization of intangibles - 844 Total costs and expenses 16,547 22,699 Loss from operations (894) (8,731) Net investment income 144 356 Net loss $(750) $(8,375) Net loss, excluding acquisition related charges (B) $(750) $(5,764) Diluted net loss per share (A) $(0.03) $(0.40) Diluted net loss per share, excluding acquisition related charges (B) $(0.03) $(0.27) Weighted average common shares outstanding -- Diluted 21,691 21,082 (A) Basic and diluted net loss per share amounts were equal in both periods presented. (B) In 2002, acquisition related charges include amortization of intangible assets and stock-based compensation. March 31, December 31, Balance sheet data (In thousands): 2003 2002 Cash, cash equivalents and marketable securities $82,866 $85,626 Working capital 61,203 54,176 Total assets 142,534 145,079 Stockholders`` equity 97,919 93,715
ArQule, Inc.
© PR Newswire
Quelle:www.finanznachrichten.de
Inpharmatica Moves Drug Discovery Business Downstream Through Acquisition
MONDAY, JUNE 23, 2003 5:08 AM
- PR Newswire
LONDON, Jun 23, 2003 /PRNewswire via COMTEX/ -- Inpharmatica Ltd, a leading informatics-driven drug discovery company, today announced that it has entered into an agreement with ArQule Inc., to acquire certain of ArQule (UK) Limited`s assets, to take an assignment of its 10,000 square foot Cambridge laboratories and to license certain of its intellectual property. Fifteen of ArQule (UK) Limited`s former staff will join Inpharmatica following the deal. Completion of the transaction is subject to certain third party consents and agreements. Financial terms of the transaction were not disclosed.
When completed, the agreement with ArQule Inc. will provide Inpharmatica, via its Cambridge site, with world leading technology and discovery expertise in the vital area of drug lead optimization. Upon completion of the transaction, Inpharmatica will, in one step, have further enhanced the capabilities of PharmaCarta(TM), the company`s chemogenomics technology platform, moved its drug discovery capabilities downstream and obtained access to fully commissioned chemistry facilities, sufficient to advance its internal discovery programs to pre-clinical phase. Inpharmatica intends to apply the newly acquired technology to the provision of in silico and in vitro ADME screening services, supported by specialist ADME consultancy, for biotechnology and pharmaceutical companies as well as applying the technology and expertise to its internal discovery programs.
PricewaterhouseCoopers Life Sciences group in Cambridge acted as advisers to Inpharmatica on the transaction.
Commenting on the announcement, Dr. Malcolm Weir, Chief Executive Officer of Inpharmatica, said:
"We are delighted with this transaction and particularly pleased that the Cambridge team elected to join Inpharmatica. They bring a wealth of pharma industry experience and state of the art expertise in an area that is proving to be critical in improving R&D productivity. The technology accessed through this agreement and the team we have recruited to support that technology improves our offering to clients and our capability for internal discovery, making PharmaCarta(TM) a technology platform that extends from gene through optimized drug."
Dr Mike Tarbit, former Managing Director of ArQule (UK) Limited and now Senior Vice President -- Preclinical R&D at Inpharmatica, further commented:
"Joining Inpharmatica offers us a very exciting opportunity to work with a cutting edge company and incorporate a wider spectrum of the factors necessary for smart library design and lead optimization into our technology platform. The availability of chemistry laboratories on the Cambridge site also provides significant scope for growth as it offers synthesis capability to drive Inpharmatica`s transition to a highly effective drug discovery operation."
SOURCE Inpharmatica Ltd
Andrew Lloyd of Andrew Lloyd & Associates, +44-1273-675100, or
allo@ala.com; or Dr Malcolm Weir, m.weir@inpharmatica.co.uk, or Dr Vimal
Mehta, v.mehta@inpharmatica.co.uk, +44-20-7074-4600, or Dr Mike Tarbit, Sr. VP
Preclinical R&D, +44-1223-424-825, all of Inpharmatica
Copyright (C) 2003 PR Newswire. All rights reserved.
MONDAY, JUNE 23, 2003 5:08 AM
- PR Newswire
LONDON, Jun 23, 2003 /PRNewswire via COMTEX/ -- Inpharmatica Ltd, a leading informatics-driven drug discovery company, today announced that it has entered into an agreement with ArQule Inc., to acquire certain of ArQule (UK) Limited`s assets, to take an assignment of its 10,000 square foot Cambridge laboratories and to license certain of its intellectual property. Fifteen of ArQule (UK) Limited`s former staff will join Inpharmatica following the deal. Completion of the transaction is subject to certain third party consents and agreements. Financial terms of the transaction were not disclosed.
When completed, the agreement with ArQule Inc. will provide Inpharmatica, via its Cambridge site, with world leading technology and discovery expertise in the vital area of drug lead optimization. Upon completion of the transaction, Inpharmatica will, in one step, have further enhanced the capabilities of PharmaCarta(TM), the company`s chemogenomics technology platform, moved its drug discovery capabilities downstream and obtained access to fully commissioned chemistry facilities, sufficient to advance its internal discovery programs to pre-clinical phase. Inpharmatica intends to apply the newly acquired technology to the provision of in silico and in vitro ADME screening services, supported by specialist ADME consultancy, for biotechnology and pharmaceutical companies as well as applying the technology and expertise to its internal discovery programs.
PricewaterhouseCoopers Life Sciences group in Cambridge acted as advisers to Inpharmatica on the transaction.
Commenting on the announcement, Dr. Malcolm Weir, Chief Executive Officer of Inpharmatica, said:
"We are delighted with this transaction and particularly pleased that the Cambridge team elected to join Inpharmatica. They bring a wealth of pharma industry experience and state of the art expertise in an area that is proving to be critical in improving R&D productivity. The technology accessed through this agreement and the team we have recruited to support that technology improves our offering to clients and our capability for internal discovery, making PharmaCarta(TM) a technology platform that extends from gene through optimized drug."
Dr Mike Tarbit, former Managing Director of ArQule (UK) Limited and now Senior Vice President -- Preclinical R&D at Inpharmatica, further commented:
"Joining Inpharmatica offers us a very exciting opportunity to work with a cutting edge company and incorporate a wider spectrum of the factors necessary for smart library design and lead optimization into our technology platform. The availability of chemistry laboratories on the Cambridge site also provides significant scope for growth as it offers synthesis capability to drive Inpharmatica`s transition to a highly effective drug discovery operation."
SOURCE Inpharmatica Ltd
Andrew Lloyd of Andrew Lloyd & Associates, +44-1273-675100, or
allo@ala.com; or Dr Malcolm Weir, m.weir@inpharmatica.co.uk, or Dr Vimal
Mehta, v.mehta@inpharmatica.co.uk, +44-20-7074-4600, or Dr Mike Tarbit, Sr. VP
Preclinical R&D, +44-1223-424-825, all of Inpharmatica
Copyright (C) 2003 PR Newswire. All rights reserved.
Arqule knapp 10% im positivem Terrain !Kaufchance jetzt nutzen !!!!!!
robby
robby
@robby13
... hier liegt nach wie vor eine ziemliche "Börsenbriefempfehlungseuphorie" vor. Während ArQule an der Nasdaq eher auf dem absteigenden Ast ist, wird die Aktie in Frankfurt gekauft, als ob es morgen keine Aktien mehr geben würde. So sieht eine Mini-Bubble aus.
merlone
... hier liegt nach wie vor eine ziemliche "Börsenbriefempfehlungseuphorie" vor. Während ArQule an der Nasdaq eher auf dem absteigenden Ast ist, wird die Aktie in Frankfurt gekauft, als ob es morgen keine Aktien mehr geben würde. So sieht eine Mini-Bubble aus.
merlone
Kommen die Zahlen am 24.07.2003?
Wie sieht die Schätzung aus?
Wie sieht die Schätzung aus?
Bei den letzten 4 Quartalsberichten hat Arqule (ARQL) immer die Erwartungen geschlagen, sollte dies auch jetzt wieder passieren und der Quartalsverlust nahe dem Break even liegen - sollten wir stark steigende Kurse sehen.
Cash ist ausreichend vorhanden und die Marktkapitalisierung ist alleine durch die Cashposition abgesichert.
Mar 2003 04/16/2003 -0.03 -0.11 N+
Dec 2002 02/13/2003 -0.1 -0.14 N+
Sep 2002 10/17/2002 -0.2 -0.318 N+
Jun 2002 07/18/2002 -0.17 -0.308 N+
Wir werden sehen.
Cash ist ausreichend vorhanden und die Marktkapitalisierung ist alleine durch die Cashposition abgesichert.
Mar 2003 04/16/2003 -0.03 -0.11 N+
Dec 2002 02/13/2003 -0.1 -0.14 N+
Sep 2002 10/17/2002 -0.2 -0.318 N+
Jun 2002 07/18/2002 -0.17 -0.308 N+
Wir werden sehen.
ArQule, Inc. has added a News Release to its Investor Relations web site.
Title: ArQule, Inc. to Report Second Quarter Financial Results on July 24, 2003
Date: 7/15/2003 4:15:00 PM
For a complete listing of our News Releases visit:
Title: ArQule, Inc. to Report Second Quarter Financial Results on July 24, 2003
Date: 7/15/2003 4:15:00 PM
For a complete listing of our News Releases visit:
@All
Gibt es hier keine Meinungenzu der gestern bekanntgegebenen Übernahme?
aceman
Gibt es hier keine Meinungenzu der gestern bekanntgegebenen Übernahme?
aceman
Achtung morgen kommen Zahlen!
Die Zahlen sind da!
Arqule Reports Second Quarter 2003 Financial Results Conference call and webcast scheduled for today at 9 a.m. Eastern Time
WOBURN, Mass., Jul 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- ArQule, Inc.
(Nasdaq: ARQL), a drug discovery and development company, today reported its
results for the second quarter ended June 30, 2003.
For the second quarter, ArQule reported revenues of $15,482,000 compared with
$16,231,000 for the same period of 2002. For the second quarter, the Company
reported net income of $1,038,000, or $0.04 per share. This compares with a net
loss of $4,928,000, or $0.23 per share, for the quarter ended June 30, 2002. Net
loss for the second quarter of 2002 included stock-based compensation and
amortization of intangibles charges of $480,000 and $843,000, respectively.
Revenues for the six months ended June 30, 2003 were $31,135,000 compared with
revenues of $30,199,000 for the first six months of 2002. For the six months
ended June 30, 2003, ArQule reported net income of $285,000, or $0.01 per share.
This compares with a net loss of $13,304,000, or $0.63 per share, for the six
months ended June 30, 2002. Net loss for the first half of 2002 included
stock-based compensation and amortization of intangibles charges of $2,190,000
and $1,687,000, respectively.
ArQule ended the second quarter of 2003 with approximately $83 million in cash
and marketable securities.
"ArQule`s solid achievements during the second quarter reinforce our strategy to
transform ArQule into an efficient drug discovery and development company," said
Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer. "While
pursuing opportunities to expand our pipeline and biological expertise --
culminating in last week`s announcement regarding the proposed acquisition of
Cyclis Pharmaceuticals -- we continued to efficiently meet all of our
collaborators` expectations. In addition, we progressed our lead internal
discovery program involving p38 MAP Kinase."
David C. Hastings, ArQule`s Chief Financial Officer, summarized the Company`s
second quarter, "ArQule`s strong financial performance was driven by continued
operating efficiencies and tight cost controls. This performance gives ArQule a
strategic advantage as we invest in our drug discovery and development
programs."
Financial Guidance
As stated in last week`s announcement, ArQule anticipates the acquisition of
Cyclis Pharmaceuticals will not affect ArQule`s previous guidance for revenue
and total operating expenses, excluding purchase accounting.
For the year, ArQule still expects revenues to range between $56 and $58
million. The total cost of revenue is expected to range between $37 and $38
million, an improvement from previous guidance of between $40 and $41 million,
due to increased operating efficiencies. ArQule now expects total research and
development expense to range between $20 and $21 million, an increase from
previous guidance of between $17 and $18 million. This reflects the anticipated
increase in development spending as ArQule expects to commence Phase I clinical
trials with Cyclis` lead compound CO-501 this year, provided the acquisition of
Cyclis closes successfully. In addition, ArQule`s research and development
expense includes the cost of the research scientists expected to join ArQule as
a result of the Cyclis acquisition. ArQule`s marketing, general and
administrative expenses are still expected to range between $10 and $11 million,
unchanged from previous guidance. ArQule`s net investment income is now expected
to range between $500,000 and $600,000, a slight reduction from previous
guidance of between $600,000 and $700,000. ArQule`s weighted average shares for
the year are expected to range between 24.5 and 25 million.
With respect to the purchase accounting for the Cyclis acquisition, ArQule
expects to incur a charge of approximately $30 million related to the in-
process research and development of Cyclis. This represents substantially all of
the purchase price paid and is subject to audit and change depending on the
final valuation of the transaction.
ArQule now expects its net loss for 2003 to range from $40 to $42 million. This
includes the impact of the estimated in-process research and development charge
of approximately $30 million to be recorded at the close of the Cyclis
acquisition.
The Cyclis acquisition, which is subject to the approval of the stockholders of
Cyclis and to customary closing conditions, is expected to close in August 2003.
ArQule now expects its net use of cash this year to range between $24 and $26
million. This is an increase from previous guidance of a net use of cash of
between $12 and $14 million for 2003 and includes payments of substantially all
Cyclis` liabilities of between $5 and $6 million and the cash portion of the
purchase price of $5 million.
ArQule will hold a conference call at 9:00 a.m. Eastern Time. Dr. Stephen A.
Hill, President and CEO, and David C. Hastings, Vice President and CFO, will
lead the call.
Date: Thursday, July 24, 2003
Time: 9:00 a.m. Eastern Time
Arqule Reports Second Quarter 2003 Financial Results Conference call and webcast scheduled for today at 9 a.m. Eastern Time
WOBURN, Mass., Jul 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- ArQule, Inc.
(Nasdaq: ARQL), a drug discovery and development company, today reported its
results for the second quarter ended June 30, 2003.
For the second quarter, ArQule reported revenues of $15,482,000 compared with
$16,231,000 for the same period of 2002. For the second quarter, the Company
reported net income of $1,038,000, or $0.04 per share. This compares with a net
loss of $4,928,000, or $0.23 per share, for the quarter ended June 30, 2002. Net
loss for the second quarter of 2002 included stock-based compensation and
amortization of intangibles charges of $480,000 and $843,000, respectively.
Revenues for the six months ended June 30, 2003 were $31,135,000 compared with
revenues of $30,199,000 for the first six months of 2002. For the six months
ended June 30, 2003, ArQule reported net income of $285,000, or $0.01 per share.
This compares with a net loss of $13,304,000, or $0.63 per share, for the six
months ended June 30, 2002. Net loss for the first half of 2002 included
stock-based compensation and amortization of intangibles charges of $2,190,000
and $1,687,000, respectively.
ArQule ended the second quarter of 2003 with approximately $83 million in cash
and marketable securities.
"ArQule`s solid achievements during the second quarter reinforce our strategy to
transform ArQule into an efficient drug discovery and development company," said
Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer. "While
pursuing opportunities to expand our pipeline and biological expertise --
culminating in last week`s announcement regarding the proposed acquisition of
Cyclis Pharmaceuticals -- we continued to efficiently meet all of our
collaborators` expectations. In addition, we progressed our lead internal
discovery program involving p38 MAP Kinase."
David C. Hastings, ArQule`s Chief Financial Officer, summarized the Company`s
second quarter, "ArQule`s strong financial performance was driven by continued
operating efficiencies and tight cost controls. This performance gives ArQule a
strategic advantage as we invest in our drug discovery and development
programs."
Financial Guidance
As stated in last week`s announcement, ArQule anticipates the acquisition of
Cyclis Pharmaceuticals will not affect ArQule`s previous guidance for revenue
and total operating expenses, excluding purchase accounting.
For the year, ArQule still expects revenues to range between $56 and $58
million. The total cost of revenue is expected to range between $37 and $38
million, an improvement from previous guidance of between $40 and $41 million,
due to increased operating efficiencies. ArQule now expects total research and
development expense to range between $20 and $21 million, an increase from
previous guidance of between $17 and $18 million. This reflects the anticipated
increase in development spending as ArQule expects to commence Phase I clinical
trials with Cyclis` lead compound CO-501 this year, provided the acquisition of
Cyclis closes successfully. In addition, ArQule`s research and development
expense includes the cost of the research scientists expected to join ArQule as
a result of the Cyclis acquisition. ArQule`s marketing, general and
administrative expenses are still expected to range between $10 and $11 million,
unchanged from previous guidance. ArQule`s net investment income is now expected
to range between $500,000 and $600,000, a slight reduction from previous
guidance of between $600,000 and $700,000. ArQule`s weighted average shares for
the year are expected to range between 24.5 and 25 million.
With respect to the purchase accounting for the Cyclis acquisition, ArQule
expects to incur a charge of approximately $30 million related to the in-
process research and development of Cyclis. This represents substantially all of
the purchase price paid and is subject to audit and change depending on the
final valuation of the transaction.
ArQule now expects its net loss for 2003 to range from $40 to $42 million. This
includes the impact of the estimated in-process research and development charge
of approximately $30 million to be recorded at the close of the Cyclis
acquisition.
The Cyclis acquisition, which is subject to the approval of the stockholders of
Cyclis and to customary closing conditions, is expected to close in August 2003.
ArQule now expects its net use of cash this year to range between $24 and $26
million. This is an increase from previous guidance of a net use of cash of
between $12 and $14 million for 2003 and includes payments of substantially all
Cyclis` liabilities of between $5 and $6 million and the cash portion of the
purchase price of $5 million.
ArQule will hold a conference call at 9:00 a.m. Eastern Time. Dr. Stephen A.
Hill, President and CEO, and David C. Hastings, Vice President and CFO, will
lead the call.
Date: Thursday, July 24, 2003
Time: 9:00 a.m. Eastern Time
Still und leise in Richtung Norden - weiter so
Keine neuen News - Kurs tritt auf der Stelle - abwarten
ARQL
ArQule, Inc. Nasdaq-NM
Back to Headlines | Previous Story
Lon Juricic Highlights the Following Stocks: Bioanalytical Systems, Carrington Labs, OSI Pharma, PAREXEL, ArQule, and Healthcare Technologies
CHICAGO, Aug 22, 2003 (BUSINESS WIRE) -- Add a little zip to your portfolio with Lon Juricic`s recommendations in the biotech sector focused on the smallest building blocks of life. Read about Bioanalytical Systems (NASDAQ:BASI), Carrington Laboratories (NASDAQ:CARN), Osi Pharmaceuticals (NASDAQ:OSIP), PAREXEL (NASDAQ:PRXL), ArQule (NASDAQ:ARQL), and Healthcare Technologies (NASDAQ:HCTL). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/
Here are the highlights from the Featured Expert column:
It has been an exciting few weeks for a couple of Lon Juricic`s portfolio stocks. In addition to his closed position in Bioanalytical Systems (NASDAQ:BASI), with a 79% gain, he is currently holding a 49% gain in Carrington Laboratories (NASDAQ:CARN), a 6.5% gain in Osi Pharmaceuticals (NASDAQ:OSIP), and an 8.5% gain in PAREXEL (NASDAQ:PRXL). ArQule (NASDAQ:ARQL) is showing a modest loss and Juricic`s sleeper stock Healthcare Technologies (NASDAQ:HCTL) is even.
Updated Positions
Healthcare Technologies Ltd. (NASDAQ:HCTL) specializes in the development, manufacture and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point-of-care sites in Israel and worldwide. HCTL is a little Israeli based sleeper stock on the NASDAQ Small Cap Index that recently grabbed Juricic`s interest. For the fiscal year ended 12/31/02, revenues rose 4% to $16.7 million and revenues for the first quarter ended March 31, 2003 were $4.3 million, up for $4.1 million for the prior year. The only problem Juricic could find with this little gem is the volume. Nobody has heard of HCTL yet - OR HAVE THEY! He thinks over the next 12 months word may start spreading about HCTL and money may start flowing into the stock.
Carrington Laboratories, Inc. (NASDAQ:CARN) is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw materials Manapol and Hydrapol; and market consumer products under the AloeCeuticals brand. CARN reported a great second-quarter. Revenues at the company climbed 83% to $8.0 million from $4.3 million. Second-quarter net income came in at $339,000, or three cents per diluted share, compared to a loss of $858,000, or nine cents per diluted share, a year earlier.
ArQule, Inc. (NASDAQ:ARQL) is a recognized leader in small-molecule chemistry, and is pursuing a strategy to become an efficient drug discovery and development company. ArQule provides high quality library design and compound production to pharmaceutical collaborators. For the second quarter, ArQule reported revenues of $15,482,000 compared with $16,231,000 for the same period of 2002. For the second quarter, the Company reported net income of $1,038,000, or $0.04 per share. This compares with a net loss of $4,928,000, or $0.23 per share, for the quarter ended June 30, 2002. Although the stock has been stagnating since Juricic`s first recommendation, recent positive developments at ARQL give him great confidence in the future of the company.
Get plenty more information on the above-mentioned companies, including their price targets, and make sure to study Lon Juricic`s new position by clicking: http://featuredexpert3bw.zacks.com/
About Zacks Featured Experts
To be a successful investor you need professional advice. Experts who know what they`re talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.
Recommendations from Featured Experts Highlighted in FREE Investment Newsletter
The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE: Zacks.com
ArQule, Inc. Nasdaq-NM
Back to Headlines | Previous Story
Lon Juricic Highlights the Following Stocks: Bioanalytical Systems, Carrington Labs, OSI Pharma, PAREXEL, ArQule, and Healthcare Technologies
CHICAGO, Aug 22, 2003 (BUSINESS WIRE) -- Add a little zip to your portfolio with Lon Juricic`s recommendations in the biotech sector focused on the smallest building blocks of life. Read about Bioanalytical Systems (NASDAQ:BASI), Carrington Laboratories (NASDAQ:CARN), Osi Pharmaceuticals (NASDAQ:OSIP), PAREXEL (NASDAQ:PRXL), ArQule (NASDAQ:ARQL), and Healthcare Technologies (NASDAQ:HCTL). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/
Here are the highlights from the Featured Expert column:
It has been an exciting few weeks for a couple of Lon Juricic`s portfolio stocks. In addition to his closed position in Bioanalytical Systems (NASDAQ:BASI), with a 79% gain, he is currently holding a 49% gain in Carrington Laboratories (NASDAQ:CARN), a 6.5% gain in Osi Pharmaceuticals (NASDAQ:OSIP), and an 8.5% gain in PAREXEL (NASDAQ:PRXL). ArQule (NASDAQ:ARQL) is showing a modest loss and Juricic`s sleeper stock Healthcare Technologies (NASDAQ:HCTL) is even.
Updated Positions
Healthcare Technologies Ltd. (NASDAQ:HCTL) specializes in the development, manufacture and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point-of-care sites in Israel and worldwide. HCTL is a little Israeli based sleeper stock on the NASDAQ Small Cap Index that recently grabbed Juricic`s interest. For the fiscal year ended 12/31/02, revenues rose 4% to $16.7 million and revenues for the first quarter ended March 31, 2003 were $4.3 million, up for $4.1 million for the prior year. The only problem Juricic could find with this little gem is the volume. Nobody has heard of HCTL yet - OR HAVE THEY! He thinks over the next 12 months word may start spreading about HCTL and money may start flowing into the stock.
Carrington Laboratories, Inc. (NASDAQ:CARN) is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw materials Manapol and Hydrapol; and market consumer products under the AloeCeuticals brand. CARN reported a great second-quarter. Revenues at the company climbed 83% to $8.0 million from $4.3 million. Second-quarter net income came in at $339,000, or three cents per diluted share, compared to a loss of $858,000, or nine cents per diluted share, a year earlier.
ArQule, Inc. (NASDAQ:ARQL) is a recognized leader in small-molecule chemistry, and is pursuing a strategy to become an efficient drug discovery and development company. ArQule provides high quality library design and compound production to pharmaceutical collaborators. For the second quarter, ArQule reported revenues of $15,482,000 compared with $16,231,000 for the same period of 2002. For the second quarter, the Company reported net income of $1,038,000, or $0.04 per share. This compares with a net loss of $4,928,000, or $0.23 per share, for the quarter ended June 30, 2002. Although the stock has been stagnating since Juricic`s first recommendation, recent positive developments at ARQL give him great confidence in the future of the company.
Get plenty more information on the above-mentioned companies, including their price targets, and make sure to study Lon Juricic`s new position by clicking: http://featuredexpert3bw.zacks.com/
About Zacks Featured Experts
To be a successful investor you need professional advice. Experts who know what they`re talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.
Recommendations from Featured Experts Highlighted in FREE Investment Newsletter
The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE: Zacks.com
Da scheint sich was zu tun...
Umsatz steigt; "Ausbruch" nach oben nach der langen Durststrecke...
Außerdem ist diese Firma recht günstig bewertet! Nur zu den alten "Burnrates" dürfen die nicht zurückkehren...
Aber für das erste Halbjahr 2003 sieht es ja schon ganz gut aus...
Gute Kaufchance würde ich sagen!
Was sagt Ihr dazu???
Gruß
Falke28
Umsatz steigt; "Ausbruch" nach oben nach der langen Durststrecke...
Außerdem ist diese Firma recht günstig bewertet! Nur zu den alten "Burnrates" dürfen die nicht zurückkehren...
Aber für das erste Halbjahr 2003 sieht es ja schon ganz gut aus...
Gute Kaufchance würde ich sagen!
Was sagt Ihr dazu???
Gruß
Falke28
Das Ding geht jetzt ab!!!
Kaufen!!!
Gruß
Falke28
Kaufen!!!
Gruß
Falke28
+14% in N.Y.
WOBURN, Mass., Sep 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- ArQule, Inc. (ARQL) , a drug discovery and development company, today announced that it has entered into a chemistry collaboration with Novartis Institutes for BioMedical Research, Inc. (NIBRI), an affiliate of Novartis AG. As part of this collaboration, ArQule will apply its integrated chemistry technology platform to generate and optimize small-molecule compounds for NIBRI`s anti-infective drug discovery program. The terms of the agreement were not disclosed.
"The addition of Novartis, one of the world`s leading R&D organizations, to our list of partners is further validation of our chemistry technologies business," said Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer. "This announcement confirms our ability to add new customers for our chemistry services while continuing to build our internal proprietary portfolio of discovery and development programs."
ArQule, Inc., a recognized leader in small-molecule chemistry, is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammatory diseases. Through its acquisition of Cyclis Pharmaceuticals, ArQule intends to combine molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with ArQule`s small-molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCE`s are small-molecule compounds designed for an optimal balance of drug-like properties. ArQule also provides high quality library design and compound production to pharmaceutical collaborators.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: ArQule may not be able to apply its technology platform to produce successfully compounds for NIBRI; ArQule may never successfully transform itself into an efficient drug discovery and development company; ArQule may not be able to successfully close the acquisition of Cyclis Pharmaceuticals, Inc., or successfully integrate the acquired technologies and assets; the possibility that anticipated benefits resulting from the acquisition of Cyclis may not be realized; unforeseen circumstances or events relating to the progress of product research and development activities in ArQule`s portfolio and projected expenditures relating thereto; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
SOURCE ArQule, Inc.
"The addition of Novartis, one of the world`s leading R&D organizations, to our list of partners is further validation of our chemistry technologies business," said Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer. "This announcement confirms our ability to add new customers for our chemistry services while continuing to build our internal proprietary portfolio of discovery and development programs."
ArQule, Inc., a recognized leader in small-molecule chemistry, is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammatory diseases. Through its acquisition of Cyclis Pharmaceuticals, ArQule intends to combine molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with ArQule`s small-molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCE`s are small-molecule compounds designed for an optimal balance of drug-like properties. ArQule also provides high quality library design and compound production to pharmaceutical collaborators.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: ArQule may not be able to apply its technology platform to produce successfully compounds for NIBRI; ArQule may never successfully transform itself into an efficient drug discovery and development company; ArQule may not be able to successfully close the acquisition of Cyclis Pharmaceuticals, Inc., or successfully integrate the acquired technologies and assets; the possibility that anticipated benefits resulting from the acquisition of Cyclis may not be realized; unforeseen circumstances or events relating to the progress of product research and development activities in ArQule`s portfolio and projected expenditures relating thereto; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
SOURCE ArQule, Inc.
Hey das sind ja klasse Neuigkeiten...
Wäre sehr gespannt auf den Inhalt dieser Vereinbarung. Könnte aber ein "Durchbruch" für Arqule gewesen sein.
Wie wollen es hoffen - denn die Aktie ist vergleichsweise noch recht billig.
Was denkt Ihr?
Gruß
Falke28
Wäre sehr gespannt auf den Inhalt dieser Vereinbarung. Könnte aber ein "Durchbruch" für Arqule gewesen sein.
Wie wollen es hoffen - denn die Aktie ist vergleichsweise noch recht billig.
Was denkt Ihr?
Gruß
Falke28
Die Firma hat eine Marktkapitalisierung von 100 Mio bei 80 Mio Cash. Das ist fast geschenkt. In der Spitze stand die Aktie bei knapp 40 $, heute nur noch bei 4,7 $.
Die Gewichtung von 6% im DAC Fonds stimmt mich ebenfalls positiv.
Der Beckmann muss für ca. 1 Mio Euro Aktien nachkaufen, wenn er diese Gewichtung bei einem Fondsvolumen von 10 Mio beibehalten möchte, dass wird den Kurs auf jeden Fall nach oben treiben.
Die Gewichtung von 6% im DAC Fonds stimmt mich ebenfalls positiv.
Der Beckmann muss für ca. 1 Mio Euro Aktien nachkaufen, wenn er diese Gewichtung bei einem Fondsvolumen von 10 Mio beibehalten möchte, dass wird den Kurs auf jeden Fall nach oben treiben.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,76 | |
| -0,07 | |
| -0,40 | |
| +2,06 | |
| +50,00 | |
| +0,65 | |
| +0,17 | |
| +0,65 | |
| -0,49 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 189 | ||
| 129 | ||
| 80 | ||
| 78 | ||
| 50 | ||
| 44 | ||
| 41 | ||
| 32 | ||
| 30 | ||
| 26 |
